{
    "clinical_study": {
        "@rank": "119511", 
        "arm_group": [
            {
                "arm_group_label": "Lidocaine HCl 2%", 
                "arm_group_type": "Active Comparator", 
                "description": "Lidocaine HCl   2% (200mg/10ml) 10 ml."
            }, 
            {
                "arm_group_label": "Lidocaine HCl   1%", 
                "arm_group_type": "Experimental", 
                "description": "Lidocaine HCl   1% (100mg/10ml)  15-20 ml."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to Prove that injection of 15 to 20 mL of lidocaine 1% into the\n      fracture site (Hematoma block) is more effective in terms of pain relieving then injection\n      of 10 mL of lidocaine 2%, and equally safe in terms of complications, for closed reduction\n      of distal radius fractures."
        }, 
        "brief_title": "Hematoma Block for Reduction of Distal Radius Fractures", 
        "condition": "Fractures of the Distal Radius", 
        "condition_browse": {
            "mesh_term": [
                "Fractures, Bone", 
                "Hematoma", 
                "Radius Fractures"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Fractures of the distal radius, with or without ulna fracture\n\n        Exclusion Criteria:\n\n          -  Children,\n\n          -  pregnant women,\n\n          -  patients with infection or suspected infection on the site for injection.\n\n          -  Patients whose condition requires general anesthesia (patients with more fractures\n             other than the distal radius and ulna, patients with many damage...)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129270", 
            "org_study_id": "158-13-EMC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lidocaine HCl 2%", 
                "description": "comparison of different dosages of drug", 
                "intervention_name": "Lidocaine HCl   2% .", 
                "intervention_type": "Drug", 
                "other_name": "ESRACAIN"
            }, 
            {
                "arm_group_label": "Lidocaine HCl   1%", 
                "description": "comparison of different dosages of drug", 
                "intervention_name": "Lidocaine  HCl 1%", 
                "intervention_type": "Drug", 
                "other_name": "ESRACAIN"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lidocaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Fractures of the distal radius", 
            "Hematoma block", 
            "Lidocaine"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "chagayor1@gmail.com", 
                "last_name": "Chagay Orbach, Dr"
            }, 
            "facility": {
                "address": {
                    "city": "Afula", 
                    "country": "Israel", 
                    "zip": "18101"
                }, 
                "name": "HaEmek medical center"
            }, 
            "investigator": {
                "last_name": "Chagay Orbach, Dr", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Hematoma Block for Reduction of Distal Radius Fractures", 
        "overall_contact": {
            "email": "chagayor1@gmail.com", 
            "last_name": "Chagay Orbach, Dr", 
            "phone": "+972525343174"
        }, 
        "overall_official": {
            "affiliation": "HaEemek Medical Center", 
            "last_name": "Nimrod Rozen, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ethics Commission", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "This study will be measured effective in terms of pain relieving with Visual Analog Scale.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability.", 
            "measure": "This study will be measured safe in terms of complications to injection.", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "HaEmek Medical Center, Israel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HaEmek Medical Center, Israel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}